Go to the list of all blogs
published in Blogs
Sep 08, 2026
Robert Half (RHI) Holds Near $41 Following -4% Dip Over the Past Month

Robert Half (RHI) Holds Near $41 Following -4% Dip Over the Past Month

Key Takeaways

  • Robert Half (RHI) shares traded near $41 in early September 2026, down roughly 4% from about $42.74 a month earlier, keeping the stock in a tight range after a volatile summer.
  • Second-quarter 2026 revenue of $1.336 billion fell 2% year over year, while diluted EPS of $0.26 declined from $0.41 in the prior-year period.
  • Talent Solutions posted its third consecutive quarter of sequential revenue growth, and permanent placement revenue returned to year-over-year growth, signaling an improving hiring backdrop.
  • Protiviti revenue fell 4.9% year over year amid margin pressure, though restructuring actions are expected to deliver roughly $45 million in annualized savings.
  • Management guided third-quarter revenue to $1.31 billion–$1.41 billion and adjusted EPS to $0.45–$0.53.

Where RHI Stands in the Market Now

Robert Half shares have been moving within a fairly narrow band of roughly $41 to $46 in recent weeks. This reflects a market balancing early signs of recovery in staffing against ongoing softness in the Protiviti consulting business. The latest price near $41 marks a modest decline of about 4% from the $42.74 close seen roughly 30 days earlier, staying well short of any major trend shift.

This steady pattern comes after a sharp selloff in late July right after the second-quarter earnings, followed by a recovery through August and a slight pullback into early September. As a key cyclical name in staffing and consulting, RHI tends to track labor-market conditions, hiring confidence, and corporate spending on professional services, making it a useful indicator of white-collar demand. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Robert Half Business Overview

Robert Half Inc. is the world’s first and largest specialized talent solutions and business consulting firm, founded in 1948 and based in Menlo Park, California. The company links skilled professionals with employers and reports through three segments: Contract Talent Solutions, Permanent Placement Talent Solutions, and Protiviti.

Its talent operations place contract and full-time staff in finance and accounting, technology, marketing and creative, legal, and administrative roles. Protiviti provides internal audit, risk, business, and technology consulting. This mix gives exposure to both flexible staffing and higher-value advisory work, with operations across North America, Europe, Asia, and Australia. Investors track the stock because its results often give an early signal on hiring trends and corporate confidence.

Recent Results and What Stood Out

The main driver behind recent price action remains the second-quarter 2026 report from late July. Revenue came in at $1.336 billion, down 2% year over year, while diluted EPS of $0.26 was below the $0.41 posted a year earlier, partly due to restructuring costs. Shares dropped initially after the release but later recovered as attention turned to the more positive underlying details.

Talent Solutions showed its third straight quarter of sequential revenue growth on an adjusted basis, and permanent placement revenue rose 2.9% year over year, pointing to firmer hiring demand. Contract Talent Solutions gross margin stayed at 39.1%, while overall Talent Solutions gross margin edged up to 47.4% from 47.1%. Management noted bill rates increased 2.3% year over year and highlighted AI integration for better recruiting efficiency. From what I see, these trends suggest gradual improvement in the core staffing side.

Protiviti revenue dropped 4.9% year over year, with gross margin falling to 13.5% from 19.7%, partly due to about $7 million in severance costs from restructuring. Those steps are expected to yield around $45 million in annualized savings. The company kept its quarterly dividend at $0.59 per share, showing ongoing focus on shareholder returns.

2026 Outlook and Key Factors to Monitor

Looking forward, the central question is whether the sequential gains in Talent Solutions can lead to sustained revenue growth while Protiviti completes its margin reset. The next quarterly report will be important for confirming that permanent placement demand keeps recovering and contract bill rates remain stable.

Broader economic conditions will continue to matter, including labor-market trends, hiring sentiment, and interest-rate paths, all of which affect demand for staffing and consulting. AI adoption could help recruiting efficiency but may also change needs for certain roles and advisory services. Protiviti’s restructuring benefits, its position in technology consulting, and the strength of the U.S. financial-services regulatory environment are other points worth following. These elements point to a measured outlook, and no single indicator should be viewed in isolation. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to gauge momentum context.

AI Tools in My Research Process

In my analysis, I often turn to Tickeron’s AI Trading Bots to simulate different scenarios and see how automated strategies might perform with names like this. It provides a useful layer of quantitative insight alongside traditional fundamentals, helping refine views on timing and risk without replacing core research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RHI

Momentum Indicator for RHI turns negative, indicating new downward trend

RHI saw its Momentum Indicator move below the 0 level on September 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In 72 of the 96 cases, the stock moved further down in the following days. The odds of a decline are at 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for RHI turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

RHI moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RHI crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

The Aroon Indicator for RHI entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RHI's RSI Oscillator exited the oversold zone, 15 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 62 cases where RHI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.

Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where RHI advanced for three days, in 151 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.

RHI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.116) is normal, around the industry mean (4.649). P/E Ratio (31.965) is within average values for comparable stocks, (90.345). RHI's Projected Growth (PEG Ratio) (5.456) is slightly higher than the industry average of (1.448). RHI has a moderately high Dividend Yield (0.064) as compared to the industry average of (0.024). P/S Ratio (0.701) is also within normal values, averaging (0.884).

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. RHI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RHI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Industry description

Other consumer services include companies that provide consumer services, and are not classified elsewhere. Travel fare aggregators, hotel bookings, consumer-to-consumer or business-to-business sales platforms are some examples of services that can be clubbed into this category. Many of such services have expanded online. Booking Holdings Inc, The Priceline Group Inc, and eBay Inc. are some major operators in this segment.

Market Cap

The average market capitalization across the Other Consumer Services Industry is 1.11B. The market cap for tickers in the group ranges from 164 to 18.76B. CTRP holds the highest valuation in this group at 18.76B. The lowest valued company is STAFQ at 164.

High and low price notable news

The average weekly price growth across all stocks in the Other Consumer Services Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 31%. HQI experienced the highest price growth at 5%, while IPDN experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Other Consumer Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 37
P/E Growth Rating: 56
Price Growth Rating: 53
SMR Rating: 81
Profit Risk Rating: 95
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
RHI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of staffing and risk consulting services

Industry OtherConsumerServices

Industry
Personnel Services
Address
2884 Sand Hill Road
Phone
+1 650 234-6000
Employees
108800
Web
https://www.roberthalf.com
Interact to see
Advertisement
MRSH stock declined approximately -9% over the past 30 days, driven by sector-wide AI disruption fears and analyst downgrades. Over the past quarter, the stock fell around -7%, amid softening insurance rates and declining fiduciary interest income.
MCO stock declined approximately -9% over the last 30 days amid profit-taking, insider selling, and sector-wide concerns in financial data analytics. Over the past quarter, shares fell around -18%, reflecting a correction from January highs despite strong Q4 2025 earnings. Key drivers include post-earnings selloff after Q4 results, analyst price target cuts, and broader market volatility in credit ratings sector.
SNOW stock declined approximately -9% over the last 30 days, from around $168 to $153, amid post-earnings profit-taking and analyst caution despite strong results. Over the past quarter, the stock fell about -31%, from near $223, reflecting broader sector pressures and valuation concerns in cloud software.
WDS stock surged +24% over the past 30 days, driven by a sharp rally in oil and LNG prices amid Middle East supply disruptions, including Strait of Hormuz issues and strikes on Qatar's Ras Laffan facility. Over the past quarter, the stock climbed +55%, reflecting sustained energy market volatility and Woodside's strong production from assets like Sangomar and Pluto LNG.
HMC stock declined -19% over the past 30 days amid major setbacks in EV strategy, including cancellation of North American EV models and up to $15.7 billion in related losses. Over the past quarter, shares fell -18%, driven by persistent auto segment weakness, tariff impacts, and revised FY2026 forecasts to a net loss. Key catalysts include March EV reassessment announcement causing a 5%+ drop, Q3 earnings beat overshadowed by one-time charges and guidance concerns, and Sony-Honda JV EV project halt.
EL stock plunged approximately -39% over the past 30 days amid merger discussions with Puig, tariff pressures, and restructuring costs, marking a highly volatile period. Over the past quarter, the stock is down around -37%, reflecting broader sector headwinds despite earlier quarterly earnings beats. Key drivers include confirmation of potential business combination with Puig sparking uncertainty, ongoing $100 million tariff impacts, and elevated restructuring expenses.
ESLT stock rose +13% over the past 30 days, driven primarily by a blowout Q4 2025 earnings report with revenue up 11% and EPS beating estimates by over 10%. Over the past quarter, shares surged +52%, fueled by a record $28.1 billion order backlog, up significantly year-over-year, amid heightened global defense demand. Geopolitical tensions in the Middle East boosted demand for Elbit's systems, alongside major contract wins totaling hundreds of millions from international clients.
EQT stock rose approximately +10% over the last 30 days, driven by strong Q4 2025 earnings beat, robust free cash flow guidance for 2026, and analyst price target increases. Over the past quarter, shares gained around +23%, fueled by operational efficiencies, natural gas price recovery, and positive sector sentiment amid LNG demand growth.
Robin Energy Ltd is a Cyprus-based shipping company focused on ocean and deep-sea freight transportation. As a holding entity, it acquires, owns, charters, and manages oceangoing tanker vessels worldwide. The core of its business lies in energy transportation services, mainly through handysize tankers and LPG carriers. In the competitive marine shipping industry, RBNE positions itself as a growth-oriented player, expanding its fleet and locking in multi-year charters. Recent developments, such as vessel acquisitions and Bitcoin treasury allocations, leave it exposed to shipping cycles and alternative asset volatility. From what I see, this mix contributes to the erratic stock price behavior we've observed amid shifting global energy demand and freight rates.
NG stock plunged -42% over the past 30 days amid sharp declines from mid-March peaks around $14, driven by profit-taking after a multi-year rally and sector-wide weakness in gold mining stocks. Over the past quarter, the stock is down -14%, reflecting volatility from early-year gains tied to financing successes offset by recent macro pressures and permitting concerns. Key drivers include gold price fluctuations due to interest rate expectations, profit-taking post-240%+ annual surge, and no immediate production revenue despite Donlin Gold project advancements.
CRBU stock declined approximately -10% over the past 30 days, reflecting volatility amid clinical updates and financing concerns. Over the past quarter, the stock rose about +12%, driven by positive earnings beats and pipeline progress. Key drivers include Q4 2025 earnings beat, vispa-cel Phase 3 plans, but offset by cash burn and need for additional capital.
Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63. The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event.
SYY shares are trading approximately -6.40% lower in premarket trading on March 30, 2026, from a prior close of $81.80 to roughly $76.56. The primary catalyst is Sysco's announcement of a $29.1 billion definitive agreement to acquire Jetro Restaurant Depot, one of the nation's largest Cash & Carry food wholesalers.
Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.
FingerMotion, Inc. (FNGR) operates as a mobile data specialist, delivering mobile payment and recharge platform solutions mainly in China. The company's core revolves around telecommunication products and services, such as top-up recharges, data plans, SMS and MMS services, big data insights for consumer behavior analysis, and rich communication services (RCS) platforms. It also provides value-added products through partnerships with telecom providers and e-commerce platforms.
NIO Inc. (NIO) stands out as a leading Chinese electric vehicle manufacturer focused on premium smart EVs. The company designs, develops, and sells high-end battery electric vehicles, bolstered by its Battery-as-a-Service model that lets customers swap batteries at stations rather than owning them. In the cutthroat Chinese EV space, NIO competes directly with firms like XPEV and LI.
Xcel Energy Inc. (XEL) stands out as a major U.S. electric and natural gas utility, serving about 3.7 million electric and 2.2 million natural gas customers across eight states, mainly in the Midwest and West. The company focuses on regulated utilities, handling electricity generation, transmission, and distribution, while increasingly prioritizing renewable sources like wind and solar. Its model centers on steady, regulated returns from infrastructure investments, backed by rate cases and recovery mechanisms.
Occidental Petroleum Corporation (OXY) stands out as a leading independent energy producer, with a primary focus on hydrocarbon exploration and production. The company has significant operations in the Permian Basin, one of the U.S.'s most productive oil regions, along with assets in the Rockies, Latin America, and the Middle East. Its business model emphasizes efficient drilling, low-cost production, and carbon capture initiatives aimed at long-term sustainability.
The ProShares UltraShort Bloomberg Natural Gas (KOLD) is a leveraged inverse exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to two times the inverse (-2x) of the daily performance of the Bloomberg Natural Gas Subindex. This subindex reflects the natural gas segment of the commodities market by tracking futures contracts, primarily the second-month Henry Hub natural gas futures, weighted by liquidity and production. The fund does not invest directly in physical natural gas but uses derivatives like futures contracts and swaps to achieve its objective.
Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.